Single-dose pharmacokinetics of once-daily cyclobenzaprine extended release 30 mg versus cyclobenzaprine immediate release 10 mg three times daily in healthy young adults: A randomized, open-label, two-period crossover, single-centre study

Clinical Drug Investigation

Volumn 28, Issue 12, 2008, Pages 793-801

  Darwish, Mona ^a   Hellriegel, Edward T ^a   Xie, Fang ^a  

^a CEPHALON INC   (United States)

Author keywords

Cyclobenzaprine, pharmacokinetics; Muscle relaxants, pharmacokinetics

Indexed keywords

AMRIX; CYCLOBENZAPRINE; DIFFUCAPS; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; CROSSOVER PROCEDURE; DIZZINESS; DOSAGE SCHEDULE COMPARISON; DRUG BLOOD LEVEL; DRUG DOSE COMPARISON; DRUG FORMULATION; DRUG TOLERABILITY; DRY SKIN; ELECTROCARDIOGRAM; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; LABORATORY TEST; MALE; MAXIMUM PLASMA CONCENTRATION; MUSCULOSKELETAL PAIN; NECK PAIN; NORMAL HUMAN; PHYSICAL EXAMINATION; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; SINGLE DRUG DOSE; SOMNOLENCE; TIME TO MAXIMUM PLASMA CONCENTRATION; VITAL SIGN;

ADULT; AMITRIPTYLINE; CROSS-OVER STUDIES; DELAYED-ACTION PREPARATIONS; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; MUSCLE RELAXANTS, CENTRAL;

EID: 55849132201     PISSN: 11732563     EISSN: None     Source Type: Journal    
DOI: 10.2165/0044011-200828120-00007     Document Type: Article

References (23)

1. Chou R, Peterson K, Helfand M. Comparative efficacy and safety of skeletal muscle relaxants for spasticity and musculo-skeletal conditions: a systematic review. J Pain Symptom Manage 2004 Aug; 28 (2): 140-75
2. van Tulder MW, Touray T, Furlan AD, et al. Muscle relaxants for non-specific low back pain. Cochrane Database Syst Rev 2003; Issue 4 (2): CD004252
3. Borenstein DG, Korn S. Efficacy of a low-dose regimen of cyclobenzaprine hydrochloride in acute skeletal muscle spasm: results of two placebo-controlled trials. Clin Ther 2003 Apr; 25 (4): 1056-73
4. Browning R, Jackson JL, O'Malley PG. Cyclobenzaprine and back pain: a meta-analysis. Arch Intern Med 2001 Jul 9; 161 (13): 1613-20
5. Nibbelink DW, Strickland SC, McLean LF, et al. Cyclobenzaprine, diazepam and placebo in the treatment of skeletal muscle spasm of local origin. Clin Ther 1978; 1 (6): 409-24
6. Katz WA, Dube J. Cyclobenzaprine in the treatment of acute muscle spasm: review of a decade of clinical experience. Clin Ther 1988; 10 (2): 216-28
7. Cramer MP, Saks SR. Translating safety, efficacy and compliance into economic value for controlled release dosage forms. Pharmacoeconomics 1994 Jun; 5 (6): 482-504
8. Reiz JL, Salem P, Darke AC. Pharmacokinetics and pharmacoterization dynamics of once-daily controlled-release oxybutynin and immediate-release oxybutynin. J Clin Pharmacol 2007 Mar; 47 (3): 351-7
9. DeVane CL. Immediate-release versus controlled-release formulations: pharmacokinetics of newer antidepressants in relation to nausea. J Clin Psychiatry 2003; 64 Suppl. 18: 14-9
10. Fuenmayor NT, Faggin BM, Cubeddu LX. Comparative efficacy, safety and kinetics of immediate- and slow-release verapamil in hispanic patients with essential hypertension. J Cardiovasc Pharmacol 1989; 13 Suppl. 4: S53-6
11. Golden RN, Nemeroff CB, McSorley P, et al. Efficacy and tolerability of controlled-release and immediate-release paroxetine in the treatment of depression. J Clin Psychiatry 2002 Jul; 63 (7): 577-84
12. Entsuah R, Chitra R. A benefit-risk analysis of once-daily venlafaxine extended release (XR) and venlafaxine immediate release (IR) in outpatients with major depression. Psychopharmacol Bull 1997; 33 (4): 671-6
13. Vetrovec GW. Once-daily therapy for angina pectoris with nifedipine gastrointestinal therapeutic system: dosing and clinical efficacy. Am J Med 1989 Jan 16; 86 (1A): 28-32
14. Schwartz S, Fonseca V, Berner B, et al. Efficacy, tolerability, and safety of a novel once-daily extended-release metformin in patients with type 2 diabetes. Diabetes Care 2006 Apr; 29 (4): 759-64
15. Amrix [package insert]. Frazer (PA): Cephalon, Inc., 2007
16. Hucker HB, Stauffer SC, Albert KS, et al. Plasma levels and bioavailability of cyclobenzaprine in human subjects. J Clin Pharmacol 1977 Nov; 17 (11-12): 719-27
17. Winchell GA, King JD, Chavez-Eng CM, et al. Cyclobenzaprine pharmacokinetics, including the effects of age, gender, and hepatic insufficiency. J Clin Pharmacol 2002 Jan; 42 (1): 61-9
18. World Medical Association. Declaration of Helsinki: ethical principles for medical research involving human subjects [online]. Available from URL: http://www.wma.net/e/policy/pdf/17c.pdf [Accessed 2008 Oct 10]
19. International Conference on Harmonisation Working Group. ICH Harmonised Tripartite Guideline: Guideline for Good Clinical Practice E6 (R1). 1996 Jun 10
20. Weil A, Narayana A, Chang SCK, et al. Efficacy of cyclobenzaprine hydrochloride extended-release 15 mg and 30 mg once-daily for low back and neck pain associated with muscle spasms: a pooled analysis of two randomized, double-blind, parallel-group, placebo-controlled, multicenter studies [abstract no. 206]. Pain Med 2008; 9 (1): 134-5
21. Weil AJ, Altman C, Chang SCK, et al. Efficacy of cyclobenzaprine hydrochloride extended-release 15 and 30 mg once daily for low back and neck pain associated with muscle spasm: a pooled analysis of two randomized, double-blind, parallel-group, placebo-controlled, multicenter studies [poster 206]. The 24th Annual Meeting of the American Academy of Pain Medicine; 2008 Feb 12-16; Orlando (FL)
22. Nichols-English G, Poirier S. Optimizing adherence to pharmaceutical care plans. J Am Pharm Assoc (Wash) 2000 Jul; 40 (4): 475-85
23. Greenberg RN. Overview of patient compliance with medication dosing: a literature review. Clin Ther 1984; 6 (5): 592-9